drugset / Trial / NCT00776724
Tailored Neoadjuvant Chemotherapy for Stage II/III Breast Cancer With Tumor Size More Than 2 cm
RandomizedParallel-groupOpen-labelTreatment
Summary
This is a multi-center randomized phase III trial. The purpose is to evaluate and compare the pathological complete response (pCR) rates after neoadjuvant chemotherapy with tailored chemotherapeutic regimens or standard chemotherapy for stage II/III breast cancer with tumor size more than 2 cm.
Timeline
- Start
- 2008-05-29
- Primary completion
- 2014-11-30
- Completion
- 2017-04-19
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cisplatin | Other / unclassified | 35 mg/m2 | Intravenous |
| Comparator | Docetaxel | Small molecule | 35 mg/m2 | Intravenous |
| Comparator | Docetaxel | Small molecule | 70 mg/m2 | Intravenous |
| Comparator | Epirubicin | Small molecule | 45 mg/m2 | Intravenous |
| Comparator | Epirubicin | Small molecule | 90 mg/m2 | Intravenous |
| Subject | Lv | Unknown | 300 mg/m2 | — |
| Subject | Vinorelbine | Small molecule | 25 mg/m2 | Intravenous |
| Subject | fluorouracil | Small molecule | 2000 mg/m2 | — |